Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
arcticnovartis
Wed, 01/31/2024 – 07:02
Read more abou…
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
arcticnovartis
Wed, 01/31/2024 – 07:02
Read more abo…
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
arcticnovartis
Fri, 01/19/2024 – 16:04
Read more about Novartis Lu…
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
arcticnovartis
Mon, 01/08/2024 – 07:19
Read more about Novartis Scemblix®…
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
arcticnovartis
Fri, 01/05/2024 – 15:32
Read more about Novartis expands production of Pluvicto™ with …
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
arcticnovartis
Wed, 12/13/2023 – 14:41
Read more about Novartis rece…
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
arcticnovartis
Wed, 12/13/2023 – 14:41
Read more about Novartis inves…
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis
Wed, 12/13/2023 – 14:41
Read more …
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
arcticnovartis
Wed, 12/13/2023 – 14:41
Read more about Latest Nov…
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
arcticnovartis
Mon, 12/11/2023 – 07:19
Read more about Novartis inves…
